

ASX RELEASE

MedAdvisor strengthens board with appointment of US based director

Melbourne, Australia, 1 February, 2022 – Medtech company, MedAdvisor Limited (**MedAdvisor** or the **Company**) (ASX: MDR) is pleased to announce that Ms RaeAnn Grossman will join the Board as a non-executive director and appointee of Cotiviti, Inc. (**Cotiviti**) effective today.

Key highlights:

- **Ms Grossman is a highly experienced US healthcare executive.**
- **She currently serves as EVP Population Health, Risk Adjustment & Quality for Cotiviti.**
- **Cotiviti is a strategic partner and the largest shareholder of MedAdvisor.**

Ms Grossman has extensive experience in US healthcare having previously held senior roles at United Healthcare's Optum, Gorman Group and Censeo. She is currently the EVP of Population Health, Risk Adjustment and Quality at Cotiviti. Cotiviti is a leading healthcare technology business owned by Private Equity firm Veritas Capital.

Cotiviti became MedAdvisor's largest shareholder by acquiring certain assets from Gainwell Technologies which acquired Nasdaq listed HMS in April 2021 and subsequently sold their non-state government business assets.

Commenting on Ms Grossman's appointment to the Company's Board, Chairman Chris Ridd said, *"Having a senior US healthcare executive appointed as a non-executive Director strengthens our board and will add significant insight, interest and alignment. We are delighted that Cotiviti has selected RaeAnn, who serves as the Executive in charge of Population Health and more specifically our strategic partner Eliza Corporation. The US is a critical market and we intend on investing in capability across the business so we can deliver on the opportunities in the world's largest medicines market."*

Commenting on her appointment, Ms Grossman said, "It's been a pleasure working with MedAdvisor since Cotiviti's recent transaction with Gainwell Technologies. I am delighted that I will be able to contribute to their strategic evolution in the US market. Cotiviti and MedAdvisor provide complimentary capabilities and we are a partner that is looking to support MedAdvisor through the next phase of its growth."

- ENDS -

This document has been authorised for release by Naomi Lawrie, Company Secretary.

For more information please contact:

Company

Simon Glover
Chief Financial Officer
corporate@medadvisor.com.au
+61 3 9095 3036

Investors

Ronn Bechler
ronn.bechler@marketeye.com.au
+61 400 009 774

Media

Greer Quinn
greer@forwardcomm.com.au
+61 433 753 557

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers patients to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects patients to tools and education materials from their preferred pharmacy. MedAdvisor works with 25,000 pharmacies in the US to deliver programs to help patients take their medication safely and effectively. In Australia, MedAdvisor has connected over 2.4 million patients through more than 70% of Australian pharmacies. MedAdvisor has partnered with Cotiviti in the US and is on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors